The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Focused on the skin?
Protecting inert surfaces by providing a barrier
Hospital Acquired Infection applications
Domestic applications
Prevents “latching” of bacteria
Skin, surfaces, clothing, sheets, air
Vulnerable areas
ICU
Operating theatres
Geriatrics / paediatrics
Healthcare-associated infection $17.1bn CAGR 6.1% (Source: BCC 2015)
Thanks to oilchemist on adv
Is this related to SBTX? Croda are presenting a webinar next Tues 27th.
Croda is excited to announce the launch of our next generation probiotic cleaning ingredient designed for both odour neutralisation and hard surface cleaning. The new ingredient uses selected bacteria strains to degrade a wide range of organic matter, offering several sustainability benefits. This natural probiotic ingredient continues to be effective several days after application, reducing the need for chemical-based cleaners.
I'm still taking AxisBiotix, since the end of January. Have seen the minor itchy dry skin on my lower calves go completely pretty early on. However, the arthritic pain in my knees and right fingers is very greatly reduced. I still take naproxen, 1 a day instead of 2. Had a setback a few weeks ago when I twisted my right knee at work, but ice, rest and a steroid jab got me going again. Now back to how I was before the injury which is great.
bigpunt, did you really invest in a company without doing your dd?
https://www.skinbiotherapeutics.com/sectors/
It's a tough nut to crack. The alternative non scientific brands have had years to build up a following, whereas OPTI Slimbiome is new, and importantly, selling at a premium that people are reluctant pay, regardless of the scientific validity.
I don't know what else they can do to get a foot in the door, apart from buying their way in via a buyout of an established heath brand, but that is something that would probably need an eye watering fundraiser.
Looks as though Ayalla are taking LPLDL to market/manufacturing? Did I miss the RNS?
https://ayalla.com.br/en/
With thanks to Trotters on adv and AJS, on Twitter I think.
HOWS THIS FOR PRODUCT DIFFERENTIATION!!!
Credit to AJS who found the SWEETBIOTIX peer review paper (published yesterday)
Key part..
Looks like this is the SweetBiotix paper - Published 13th July 2022 'Published by American Chemical Society' - Kolida, Rastall, et all - sponsors Optibiotix
Skim read, some extracts ??
'This study was conducted to investigate the sweetness intensity and the potential fecal microbiome modulation of galactooligosaccharides in combination with enzymatically modified mogrosides (mMV-GOS), both generated through a patented single-pot synthesis. Sweetness intensity was performed in vivo by trained sensory panelists...In conclusion, these substrates could be considered as novel candidate prebiotic sweeteners, foreseeing a feasible and innovative approach targeting the sucrose content reduction in food. This new ingredient could provide health benefits when evaluated in human studies by combining sweetness and prebiotic fiber functionality.'
'Our data have shown that mMV-GOS, obtained by the simultaneous synthesis of GOS and modified mogrosides using bacterial ß-galactosidases, can generate products with the potential to positively modulate the human fecal microbiota in vitro, generating metabolites such as propionate and butyrate that are involved in appetite regulation (47) and also in tight junction integrity and anti-inflammatory properties that play an important role in improving type II diabetes inflammation processes. The potential prebiotic activity of mMV-GOS is an added benefit in combination with the sweetness profile.'
'In conclusion, these in vitro analyses and sweet taste studies suggest that the simultaneous synthesis of modified mogrosides and GOS could exert a prebiotic functionality, which warrants further studies investigating the effects of this novel ingredient under in vivo conditions representing physiologically human-relevant exposure scenarios. In this context, these substrates could be considered as a novel candidate prebiotic sweetener by combining sweetness and prebiotic fiber functionality, providing a feasible and innovative approach to reducing the sucrose content in food products.'
https://pubs.acs.org/doi/10.1021/acs.jafc.2c01363